Gilead Sciences

Gut stomach
Biotech

Gilead, Arcus keep TIGIT dream alive with 27-month OS data

Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months.
James Waldron Oct 13, 2025 7:05am
Glowing puzzle piece fitting into puzzle

Gilead pumps up virology pipeline with drug transporter deal

Sep 29, 2025 10:35am
Numbers and boxes floating on a blue digital background

One-third of data collected in trials may be unnecessary: study

Sep 19, 2025 11:01am
Sign warning about erosion on a cliff

Gilead's Kite erodes $2.3B Shoreline cell therapy deal

Sep 3, 2025 3:18pm
liver disease fibrosis NASH NAFLD cancer cirrhosis liver

Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen

Aug 29, 2025 10:59am
Dried up river bed

Cell therapy biotech Appia shuts down as funding runs dry

Aug 25, 2025 5:55pm